FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events

FibroBiologics, Inc.

Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.
In vivo EAE model: HDFs suppressed Th17, expanded Tregs, stimulated remyelination, outperformed adipose/bone marrow MSCs.
Company designing phase II trial to test various HDF spheroid doses and multiple-dose treatments over 18 months.
Presentation at ACTRIMS Forum 2024 on Feb 29 in West Palm Beach, FL (poster P341).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.